Integrated Radiology & Pathology Diagnostic Services: The Time is Now at UCLA

Similar documents
Data Mining for Genomic- Phenomic Correlations

Preparing an RFP for a Digital Pathology System

Session: Innovative Technologies

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

STUDY INFORMATION Principal Investigator: Phone: Primary Coordinator: Phone:

Billing Contact: Phone: Research Funding: NIH Funded Industry Funded Department Funded Short Study Protocol Title:

Notice of Faculty Disclosure

Sectra Digital Pathology Solution

Le banche dei tessuti

Digital Cytopathology & Interactive Case Discussion

Laboratory Accreditation Test Validation: A Brave New World for Anatomic Pathology

POET REPORT Perspectives on Emerging Technology

Knight Cancer Institute Cancer Early Detection Advanced Research Center (CEDAR) Call for Clinical Matched Case Control Sample Collection

The Next Revolution in Endoscopic Ultrasound Guided Biopsy Products

Setting The study setting was secondary care. The economic study was carried out in the USA.

NHS ENGLAND BOARD PAPER

Asterand Bioscience Strategic Alliances

Uniform Labeling of Blocks and Slides in Surgical Pathology

2013 Continuing Compliance Master Series Checklist Updates for Anatomic Pathology. Gerald A. Hoeltge, MD, FCAP July 17,

Preanalytical Variables in Blood Collection: Impact on Precision Medicine

M1741 Validating a Whole Slide Imaging System A Case Based Approach to the CAP Guidelines

Telepathology. and The Future of Pathology (or Why did we change our Practice Model) Jagdish Butany, MBBS, MS, FRCPC

Smart digital pathology. Share expertise in real time, not just images

Automated Breast Volumes. Simplified.

DIAGNOSE AND TREAT WITH ANTIBODIES THAT RECOGNIZE NATIVE HUMAN PROTEIN EPITOPES IN BLOOD AND TISSUE

What pathologists do: (clinically)

Central Laboratory Services. Anatomic Pathology Histology Services

Introducing a new take on efficient workflow: Deeply integrated clinical applications

Enterprise XDS based VNA

Clinical and Research Questions

Cisco Connected Imaging

WORKFLOW CHECKLIST SEATTLE VISIT

Aligning Lab Goals & Institutional Goals Laughlin Rice

Appendix B. The Curriculum in Cytotechnology for Entry-level Competencies

TheraLin. Universal Tissue Fixative Enabling Molecular Pathology

UNIVERSITY OF PATHOLOGY INFORMATICS CERTIFICATE OF COMPLETION PROGRAM. Course Program Syllabus

Personalized Healthcare Diagnostik und Therapie aus einer Hand

Accepted Manuscript. Tag, You re It! Finding and Treating Early Lung Cancers in a Single Setting. Ngoc-Quynh Chu, MD, Yolonda L.

University Of Pathology Informatics Certificate Of Completion Program

2010 NORTH AMERICAN TISSUE DIAGNOSTICS PRODUCT LINE STRATEGY AWARD

Surgical/Cytology Specimen Collection and Handling

Measure #262: Image Confirmation of Successful Excision of Image-Localized Breast Lesion National Quality Strategy Domain: Patient Safety

ENSURING YOUR ENTERPRISE IMAGE-VIEWER WORKS WITH CURRENT INFRASTRUCTURE

Risk Mitigation in Breast Predictive Factor Testing. Elizabeth H Hammond MD

Regulatory Challenges and Opportunities for Digital Pathology

What to collect and is it fit for purpose?

Manitoba Centre for Proteomics and Systems Biology 10th Anniversary

NIST Medical Imaging Informatics Activities. Medical Imaging

Interventional radiology suite or hybrid operating room: Which is the best for lung nodule localization?

Streamline Pre-Analytic Orchard Pathology Processes

Pathology Review: on DVD! Pulmonary, Gastrointestinal, Soft Tissue and Dermatopathology for the General Pathologist

Virtual Microscopy: The UCL experience. Marco Novelli

Quality ID #262: Image Confirmation of Successful Excision of Image-Localized Breast Lesion National Quality Strategy Domain: Patient Safety

Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology

Bioresearch Monitoring Inspections in Vitro Diagnostics Devices

DECLARATION OF ANDREW SAXON, M.D. knowledge, and if called to testify, I could competently do so.

Accelerating the Adoption of Companion Diagnostics

Get To The Heart Of Your Cardiology Workflow

Ariol. Clinical IHC and FISH Breast Marker Analysis Quality. Efficiency. Confidence.

What pathologists do: (clinically)

Billing Contact: Phone: Type of Research: NIH Funded Industry Funded Department Funded Study Name: CTRC Protocol: Start Date: End Date:

POTENTIAL OF BIOBANK INFORMATION SYSTEM WITHIN COMPLEX RESEARCH PROCESSES

Tendencias en Informatica de Salud

Information Technology for Genetic and Genomic Based Personalized Medicine. Submitted. April 23, 2008

BOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board of the development of an NHS England Personalised Medicine Strategy.

DEDUCE Clinical Text: An Ontology-based Module to Support Self-Service Clinical Notes Exploration and Cohort Development

APPENDIX: TECHNICAL and OPERATIONAL ISSUES of the NEPTUNE. The FDA has not approved the use of WSI for the making primary

Digital pathology: the Swedish project

University of New Mexico Health Sciences Center Office of Research Policy for the Oversight of Human Tissue in Research

Medical Devices; Immunology and Microbiology Devices; Classification of the Next Generation

Paul Valenstein, MD Synopsis. Whole Slide Imaging: Regulation and Validation

Emerging PACS Trends that Increase Imaging and Diagnostics Efficiency and Effectiveness

(introductory lecture)

IMI: Accelerated Drug Portal. Julia Brosnan on behalf of Innovative Medicines Initiative

143 Changes on the Horizon-An Update on Pathology Convergence. Bruce Friedman MD Richard Friedberg MD

From Isolation to Insights

Corporate Medical Policy

CARESTREAM RIS/PACS SuperPACS Architecture. A Changing Landscape

Using Human Tissue in Translational Research and Clinical Trials

Implementing Biomedical Informatics Approaches to Facilitate Translational and Clinical Research

THE WHITE HOUSE Office of the Vice President

IBBL: Introduction to Biobanks and their services

Personalized Medicine A new challenge for applied human pharmacology?

UE Biopathologie et Biobanking

for exceptional care

Corporate Medical Policy

Corporate Medical Policy

Survey of Neural Networks in Digital Pathology and Pathology Workflow

Introduction of virtual microscopy in routine surgical pathology - a hypothesis and personal view from Europe

Enterprise Imaging Building a Solutions Roadmap

SOLUTIONS Express Enterprise SP Enterprise XP Integral Breast Workspace. better images mean better results

General Comments. Misinformation in Immunohistochemistry. Common Misinformation s in Immunohistochemistry 4/13/2017

TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS

Higher National Diploma Biomedical Science

Ingenia MR-OR. MR Systems. Confident decision making with intraoperative insights

Megan Schmidt Vice President of Product Management, CompuGroup Medical

The interoperability opportunity: Improving healthcare with an end-to-end enterprise strategy

Outline. Impact on Human Diseases Basis for Molecular Assay Novel Biomarkers

Tech Note. Using the ncounter Analysis System with FFPE Samples for Gene Expression Analysis. ncounter Gene Expression. Molecules That Count

NAVIFY. NAVIFY Decision Support portfolio Implementation and Integration

Transcription:

Integrated Radiology & Pathology Diagnostic Services: The Time is Now at UCLA Scott W Binder MD Pritzker Professor of Clinical Pathology and Dermatology Senior Vice Chair Director, Pathology Clinical Services Geffen UCLA School of Medicine The UCLA Radiology / Pathology Project is a joint collaboration / venture between the two departments and the Ronald Reagan-UCLA Medical Center. It is intended to create a new service in imaging and molecular diagnosis by combining state of the art, minimally invasive image-guided biopsy with rapid cytological review and tissue processing for biomolecular markers.

The service will have the capacity to provide combined cyto-histopathological and clinical diagnoses, clinical staging and ultimately molecular prognosis and response prediction in patients presenting for biopsy of indeterminate lesions in solid organs. The intended users of this new service will include both UCLA Enterprise and non-ucla clinicians and patients. These physicians will refer patients to UCLA for percutaneous biopsy of indeterminate lesions for classical cytological / histologic and immunohistochemical analyses as well as biomolecular analyses as these assays become available.

Objectives To consolidate the imaging, reporting, laboratory and patient record data from multiple separate proprietary systems (6-9+) to allow integrated access and reporting to a diverse user population. To build the system in such a way that each component is self-contained, exchanges information in a standard manner, and allows third-party and direct access. To avoid the use of platform or vendor-specific technologies. Users The system will be used by both technical and non-technical users drawn from the following populations: Clinicians (UCLA Enterprise and non-enterprise) Pathologists (UCLA Enterprise and non-enterprise) Radiologists Administrators Researchers Education: Faculty and students Many users have overlapping roles. While segregation of identified and non-identified patient data may facilitate compliance, there must be a mechanism in place to easily toggle between the two for users in dual clinical-research roles.

Scale UCLA is a large clinical, teaching and research enterprise spanning multiple campuses, in partnership with other organizations and local clinics under the UCLA brand. We may acquire and partner with other organizations in the future. Additionally, because of our role in serving physicians and researchers in the community, our affected user base will likely be in the hundreds, if not thousands. Thus, any warehousing and/or web interface system should be built to scale easily, with the expectation that it will serve a much wider audience than just the Radiology/Pathology staff and in-house clinicians at UCLA Westwood and Santa Monica. Security Anonymization for HIPAA compliance in a safe environment is a requirement for each component. As such, each component must be secured against external threat at the application, operating system, and hardware level. Messaging exchanges throughout all components and levels of the system must be digitally secure. RadPath platform will be logged at the system and application levels.

s Dr. Clinician wants to review the integrated molecular report and imaging on Patient Sally Smith. Dr. Clinician goes to a dedicated web site and accesses the information on Sally Smith, including diagnostic and interventional radiology images, pathology and immunohistochemical stains of target tissue, and the molecular analysis and corresponding images from gene mutation studies, microarray analysis, and FISH. Dr. Clinician reviews all information on all patients referred to UCLA for percutaneous biopsy and molecular analyses. She is interested in receiving the data in tabular format to include various fields: MRN, data of procedure, histologic diagnosis, IHC stains performed, etc.

Office Staff of Dr. Clinician enters the system to create a PDF that serves as the source document for the patient s chart. Dr. Jones has instructed him to capture the following on the PDF: patient demographics, pathology diagnoses, diagnostic radiology interpretation, interventional biopsy images, and H&E stains, IHC stains, and FISH image. Dr. Radiologist wants to review the final molecular pathology results on her biopsy case three days earlier. The routine histologic and IHC analyses are available. The molecular results have not been entered into the report yet. She requests an autopage or email when the results are on line as part of the integrated report.

Dr. Radiologist wants to review his results of the past one year with respect to percutaneous biopsy yield and complications. He is interested in seeing in tabular form all patients he specifically has biopsied, the types of equipment used, the number of passes obtained, final diagnoses, and complications. Dr. Pathologist wants to review the findings of a particular case (an unusual or rare tumor diagnosis) with a group of residents and fellows for educational purposes.

Dr. Researcher needs to determine if there is sufficient tissue available to perform a new molecular test on the last 100 patients with a tissue diagnosis of lung adenocarcinoma. The purpose is to evaluate a prognostic biomarker panel and compare it to traditional clinical and stage variables. She queries the database for patients who have undergone percutaneous biopsy and subsequent surgical resections. Dr. Researcher intends to perform gene expression analyses on all patients with Stage I-II adenocarcinoma with BAC features to compare differential gene expression signatures relative to outcomes.

Dr. Pathologist is interested in an accessible database to be used at conferences (tumor boards) on patient management. The interface should facilitate conference preparation and be flexible during presentation, e.g., to be able to readily bring up cases not previously listed as a conference case. The images need to allow for virtual microscopy review. Dr. Pathologist needs to review and correlate previous and concurrent biopsies, including frozen sections, from his office, thus obviating the need to pull and track down old cases. This is necessary to improve turn-around time and speed up intra-operative consultation.

Dr. Pathologist and Dr. Radiologist both need a single source for pathology and radiology reports to better correlate disease processes. Ms. Administrator is interested in determining the average cost per patient who is encountered through the RP joint venture. She would like to categorize patients by biopsy type, organ system, diagnoses, imaging modality, number of different pieces of equipment (needles, etc.) used, traditional and molecular analyses performed. She will present summary information regarding average cost per patient by organ system, and by imaging modality, including average number of specimens obtained and needle/core instruments used.